Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$1.71BAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John V. Oyler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12,000
- Beta
- 0.52
- Country
- CH
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 6.25
Financials
Revenue
$1.71B+674.3%Net Income
$237.01MEBITDA
$392.71MFree Cash Flow
$595.89MEPS (diluted)
$26.65Shares Outstanding (diluted)
115.80M+251.6%Operating Expenses
$1.21BCash & Debt
$5.10BRevenue by Segment (annual)
$6.79BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $5.34B | $286.93M | $33.80 |
| 2024 | $3.81B | $-644.79M | $-6.12 |
| 2023 | $2.46B | $-881.71M | $-8.45 |
| 2022 | $1.42B | $-2.00B | $-19.37 |
| 2021 | $1.18B | $-1.46B | $-15.21 |
| 2020 | $308.87M | $-1.62B | $-19.11 |
| 2019 | $428.21M | $-948.63M | $-15.86 |
| 2018 | $198.22M | $-673.77M | $-12.09 |
| 2017 | $238.39M | $-93.11M | $-2.21 |
| 2016 | $1.07M | $-119.22M | $-3.90 |
| 2015 | $8.82M | $-57.10M | $-1.82 |
| 2014 | $13.04M | $-18.28M | $-0.35 |
| 2013 | $11.15M | $-7.49M | $-1.43 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.87
- Implied price
- $34.79
- Return from $358.07
- -37.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $17.30 — -95.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -2.0% | -49.4% | -45.9% | -43.1% | -40.7% | -38.7% |
| 3.0% | -46.8% | -43.1% | -40.2% | -37.7% | -35.6% |
| 8.0% | -44.2% | -40.3% | -37.3% | -34.7% | -32.5% |
| 13.0% | -41.6% | -37.6% | -34.4% | -31.7% | -29.4% |
| 18.0% | -39.1% | -34.8% | -31.5% | -28.7% | -26.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
40-20.00%Social Signal Score
Mentions (5)
- Newsinvestors.com·4d ago·Negative
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.
View source ↗ - Newsbusinesswire.com·35d ago·Positive
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver …
View source ↗ - Newsbusinesswire.com·36d ago·Neutral
…ces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as fi…
View source ↗ - Newszacks.com·39d ago·Neutral
BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy? Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors?
View source ↗ - Newsbusinesswire.com·49d ago·Neutral
…o Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries SAN CARLOS, Calif. & SEATTLE--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, together with the BeOne Care Foundation, a nonprofit charitable foundation, and The Max Foundation, a leading global health nonprofit organization, today announced the renewal of their partnership through 2028 to expand acc…
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $1.87 per share
Typical surprise +51.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$2.05 vs $1.63beat
- Wed, May 6$1.96 vs $0.73beat
- Thu, Feb 26$0.58 vs $1.60miss
- Thu, Nov 6$1.09 vs $0.72beat
- Wed, Aug 6$0.84 vs $0.48beat
- Wed, May 7$1.22 vs $-0.71beat
Estimates and results for ONC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ONC officers and directors.
- Bought
- —
- Sold
- $179.5m
0 trades
76 trades
- Lee Chan Henrysold
- Wang Xiaodongsold
- Wang Xiaodongsold
- Wang Xiaodongsold
- Wang Xiaodongsold
- Wang Xiaodongsold
- Wang Xiaodongsold
- Wang Xiaodongsold
24 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ONC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.